Navigation Links
Watson to Present at Goldman Sachs Global Healthcare Conference 2012
Date:5/29/2012

PARSIPPANY, N.J., May 29, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Goldman Sachs Global Healthcare Conference 2012 on Wednesday, June 6, 2012 at 8:00AM Pacific Time at the Terranea Resort in Rancho Palos Verdes, California.  The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com.  The webcast can also be accessed at the following URL:

http://cc.talkpoint.com/gold006/060512a_lr/?entity=56_TENUU86

An archived version will be available approximately four hours after the live presentation ends and can be accessed at the same locations for 90 days.

About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology.  Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business.  Watson has operations in many of the worlds established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com. CONTACTS:Investors:Lisa DeFrancesco (862) 261-7152Media:Charlie Mayr(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Watsons GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
2. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
3. Watson Confirms Renvela® Patent Challenge
4. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
5. Watson Acquires Specifar Pharmaceuticals
6. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
7. Pandora Founder Tim Westergren and Co-Discoverer of DNA Dr. James Watson Meet
8. Watsons Generic Yaz(R) Receives FDA Approval
9. Watsons Generic BONIVA® 150mg Receives FDA Approval
10. InterMune to Present at Canaccord Adams Conference
11. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... manufacturing company, today announced several positive developments that position the Company for the ... result of the transaction, Craig F. Kinghorn has been appointed Chairman of the ...
(Date:5/25/2016)... ... 2016 , ... Founder of the Fitzmaurice Hand Institute in ... of the hand by the National Board of Physicians and Surgeons, as of ... in his pursuit of providing the most comprehensive, effective treatment for his patients, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. ... the company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar ... FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is ...
(Date:5/23/2016)... ... ... need for blood donations in South Texas and across the nation is growing. , But ... blood donations are on the decline. In fact, donations across the country are at their ... Texas in the last four years alone. , There is no substitute for blood. , ...
Breaking Biology Technology:
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/15/2016)... 15, 2016 Yissum Research Development Company ... company of the Hebrew University, announced today the formation ... technology of various human biological indicators. Neteera Technologies has ... from private investors. ... detection of electromagnetic emissions from sweat ducts, enables reliable ...
(Date:3/11/2016)... , March 11, 2016 ... new market research report "Image Recognition Market by Technology ... (Marketing and Advertising), by Deployment Type (On-Premises and Cloud), ... To 2022", published by MarketsandMarkets, the global market is ... to USD 29.98 Billion by 2020, at a CAGR ...
Breaking Biology News(10 mins):